<DOC>
	<DOCNO>NCT00182806</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Irinotecan may also increase effectiveness gemcitabine . Giving irinotecan together gemcitabine may kill tumor cell . PURPOSE : This phase II trial study well give irinotecan together gemcitabine work treat patient recurrent progressive stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Irinotecan Gemcitabine Treating Patients With Recurrent Progressive Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate ( complete partial response ) patient recurrent progressive stage IIIA-IV non-small cell lung cancer treat irinotecan gemcitabine . Secondary - Determine median time progression patient treat regimen . OUTLINE : This non-randomized , open-label , multicenter study . Patients receive irinotecan IV 90 minute day 1 8 gemcitabine IV 30 minute day 2 9 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month every 8 week thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study within 16 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) , meet 1 follow stage criterion : Stage IIIA IIIB disease Progressive disease Stage IV disease Failed 1 prior platinumbased chemotherapy regimen , include adjuvant therapy Measurable evaluable disease , define 1 follow criterion : At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR &gt; 10 mm spiral CT scan Lesions apparent CT scan meet criterion measurability Brain metastases allow provided patient receive definitive therapy metastasis , asymptomatic , extraCNS metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy More 12 week Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST ALT ≤ 1.5 time normal Alkaline phosphatase &lt; 1.5 time normal Bilirubin ≤ 1.3 mg/dL Renal Creatinine ≤ 1.6 mg/dL OR Creatinine clearance ≥ 50 mL/min Cardiovascular No unstable angina No congestive heart failure No myocardial infarction within past 3 month No lifethreatening ventricular arrhythmia require maintenance therapy Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion study treatment No uncontrolled seizure disorder No uncontrolled diabetes mellitus No active infection require systemic therapy No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No unstable serious condition PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy Prior irinotecan allow No prior gemcitabine No 1 prior chemotherapy regimen NSCLC , exclude gefitinib No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other More 1 month since prior participation another clinical trial use investigational agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>